Aussie researchers have used CRISPR gene editing tools to “armor” chimeric antigen receptor (CAR) T cells to activate additional cancer-fighting proteins at the tumor site, enabling them to target cancer cells in solid tumors.
Deciphera Pharmaceuticals LLC has identified phosphatidylinositol 3-kinase catalytic subunit type 3 (PIK3C3; Vps34) inhibitors reported to be useful for the treatment of cancer.
Alterome Therapeutics Inc. has synthesized RAC-α serine/threonine-protein kinase (AKT1; PKB α) (E17K mutant) inhibitors reported to be useful for the treatment of cancer.
A team of researchers at the University of British Columbia investigated the potential of radiopharmaceutical therapy based on Terbium-161 (161Tb) both in vitro and in vivo using a novel tracer, [161Tb]Tb-BL34L20S, which uses the C-X-C chemokine receptor type 4 (CXCR4)-targeting peptide BL34L20S labeled to 161Tb.
Pancreatic ductal adenocarcinoma (PDAC) is the most prevalent form of pancreatic cancer and presents a 5-year survival rate of less than 10%. Novel therapies focusing on targeting the tumor microenvironment and dysregulated molecular signaling pathways are emerging as potential options for intervention.
Astrazeneca AB has disclosed proteolysis targeting chimera (PROTAC) compounds comprising an E3 ubiquitin ligase-binding moiety coupled to an interleukin-1 receptor-associated kinase 4 (IRAK-4)-targeting moiety through a linker acting as IRAK-4 degradation inducers reported to be useful for the treatment of cancer, inflammation, autoimmune diseases and respiratory disorders.
One of the functions of tumor-associated macrophages (TAMS) is to protect the tumor against the immune system, inhibiting T-cell engagement and reducing the efficacy of checkpoint inhibitors. Polyamidoamine hydroxyl dendrimers (HDs) target TAM without the need of a targeting ligand and are retained by TAMs for up to 1 month allowing radiation to deposit in the tumor.
RSS
